Your browser is no longer supported. Please, upgrade your browser.
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own0.20% Shs Outstand183.21M Perf Week-1.66%
Market Cap15.21B Forward P/E173.02 EPS next Y0.48 Insider Trans-8.95% Shs Float182.54M Perf Month-7.13%
Income-45.70M PEG- EPS next Q-0.32 Inst Own94.90% Short Float5.61% Perf Quarter15.80%
Sales1.85B P/S8.23 EPS this Y117.90% Inst Trans-2.63% Short Ratio6.86 Perf Half Y5.78%
Book/sh23.29 P/B3.57 EPS next Y230.60% ROA0.30% Target Price116.68 Perf Year-0.12%
Cash/sh5.89 P/C14.09 EPS next 5Y32.16% ROE0.40% 52W Range71.59 - 92.17 Perf YTD-6.00%
Dividend- P/FCF83.53 EPS past 5Y15.10% ROI0.20% 52W High-9.89% Beta0.50
Dividend %- Quick Ratio3.00 Sales past 5Y15.90% Gross Margin74.20% 52W Low16.01% ATR3.09
Employees3059 Current Ratio4.50 Sales Q/Q-14.30% Oper. Margin-3.30% RSI (14)41.26 Volatility3.90% 3.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-146.10% Profit Margin0.90% Rel Volume0.47 Prev Close83.70
ShortableYes LT Debt/Eq0.25 EarningsOct 27 AMC Payout0.00% Avg Volume1.49M Price83.05
Recom1.70 SMA20-4.20% SMA50-3.95% SMA2002.73% Volume707,990 Change-0.78%
Nov-22-21Upgrade William Blair Mkt Perform → Outperform
Oct-07-21Resumed Jefferies Buy $100
Sep-09-21Upgrade Stifel Hold → Buy $86 → $96
Jun-04-21Resumed Robert W. Baird Outperform $101
Apr-26-21Resumed Credit Suisse Outperform $102
Mar-04-21Resumed Guggenheim Buy
Mar-01-21Upgrade Evercore ISI In-line → Outperform $90 → $100
Aug-20-20Downgrade William Blair Outperform → Mkt Perform
Aug-20-20Downgrade Citigroup Buy → Neutral $148 → $86
Aug-19-20Downgrade Stifel Buy → Hold $127 → $100
Aug-19-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
Jan-26-22 09:38AM  
Jan-20-22 09:38AM  
Jan-19-22 09:38AM  
08:56AM  
Jan-14-22 04:51PM  
Jan-12-22 11:10AM  
03:48AM  
Jan-10-22 08:34AM  
07:55AM  
06:29AM  
Jan-09-22 03:13PM  
Jan-04-22 05:08PM  
06:00AM  
Dec-31-21 06:18PM  
Dec-30-21 06:01PM  
06:52AM  
Dec-29-21 06:01PM  
Dec-28-21 05:49PM  
Dec-27-21 09:38PM  
Dec-24-21 06:18PM  
Dec-22-21 08:42PM  
06:15PM  
04:20PM  
04:00PM  
11:00AM  
Dec-21-21 10:01PM  
06:38PM  
01:40PM  
01:16PM  
01:00PM  
11:43AM  
08:00AM  
Dec-20-21 05:29PM  
02:28PM  
10:04AM  
09:50AM  
07:45AM  
Dec-19-21 09:36PM  
08:24AM  
Dec-18-21 10:15AM  
Dec-17-21 06:18PM  
05:38PM  
04:10PM  
12:00PM  
08:00AM  
Dec-16-21 07:30PM  
04:27PM  
04:05PM  
04:00PM  
12:35PM  
09:55AM  
04:04AM  
Dec-15-21 09:57PM  
07:20PM  
06:15PM  
04:05PM  
01:20PM  
07:45AM  
Dec-14-21 10:09PM  
09:00PM  
08:08PM  
10:00AM  
09:40AM  
07:45AM  
Dec-13-21 06:38PM  
05:38PM  
01:20PM  
08:35AM  
Dec-10-21 03:00PM  
01:15PM  
08:10AM  
Dec-09-21 09:00PM  
04:30PM  
11:00AM  
07:45AM  
Dec-08-21 10:45AM  
08:15AM  
Dec-07-21 05:13PM  
02:15PM  
01:26PM  
12:18PM  
11:00AM  
Dec-06-21 04:44PM  
12:45PM  
Dec-05-21 11:42AM  
Dec-04-21 05:00AM  
Dec-03-21 07:56PM  
06:32PM  
11:30AM  
11:00AM  
08:35AM  
Dec-02-21 11:37PM  
06:30PM  
03:13PM  
01:33PM  
12:00PM  
09:48AM  
08:20AM  
Dec-01-21 08:07PM  
06:29PM  
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAWLIS V BRYANDirectorJan 14Option Exercise37.464,250159,20528,220Jan 19 06:34 PM
LAWLIS V BRYANDirectorJan 14Sale87.614,250372,34223,970Jan 19 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 13Option Exercise37.465,000187,300308,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 13Sale87.865,000439,300303,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 12Option Exercise37.465,000187,300308,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 12Sale89.005,000445,000303,789Jan 14 08:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 16Option Exercise37.466,000224,760309,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 16Sale84.686,000508,080303,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 15Option Exercise37.466,000224,760309,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 15Sale82.716,000496,260303,689Dec 17 07:03 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 01Sale87.221,500130,832304,389Dec 02 09:42 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 26Sale73.602,739201,59055,853Oct 28 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 20Option Exercise37.461,00037,460305,839Oct 22 04:36 PM
Davis George EricEVP, General CounselAug 02Sale76.695,518423,17558,590Aug 04 04:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 21Option Exercise37.461,00037,460304,839Jun 23 05:04 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Option Exercise26.498,513225,509312,352May 12 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 10Sale77.298,513657,970303,839May 12 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Option Exercise26.4925,000662,250328,839May 10 09:07 PM
Mueller BrianEVP, Chief Financial OfficerMay 07Option Exercise28.236,709189,39538,066May 11 07:42 PM
Mueller BrianEVP, Chief Financial OfficerMay 07Sale79.506,709533,36631,357May 11 07:42 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Sale78.1225,0001,953,121303,839May 10 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Option Exercise26.4925,000662,250328,839May 10 09:07 PM
MEIER RICHARD ADirectorMay 06Option Exercise26.4915,000397,35099,340May 07 07:48 PM
MEIER RICHARD ADirectorMay 06Sale78.385,068397,24594,272May 07 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Sale78.2925,0001,957,199303,839May 10 09:07 PM
Davis George EricEVP, General CounselMay 03Sale78.304,673365,89664,108May 04 08:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 30Option Exercise37.461,00037,460303,498May 03 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Option Exercise26.4910,000264,900312,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Sale79.3410,000793,400302,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 22Option Exercise26.4910,000264,900312,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 22Sale78.9110,000789,100302,498Apr 26 08:44 PM
Davis George EricEVP, General CounselApr 19Option Exercise26.492,70971,76171,149Apr 20 09:53 PM
Davis George EricEVP, General CounselApr 19Sale79.582,709215,58268,440Apr 20 09:53 PM
LAWLIS V BRYANDirectorApr 15Option Exercise26.497,500198,67526,350Apr 19 04:09 PM
LAWLIS V BRYANDirectorApr 15Sale76.907,500576,75018,850Apr 19 04:09 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 08Sale78.811,537121,13158,250Apr 09 05:57 PM
Mueller BrianEVP, Chief Financial OfficerApr 01Sale76.305,692434,30031,016Apr 02 07:35 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 24Sale76.301,18190,11061,439Mar 26 05:45 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 18Sale77.991,308102,01164,133Mar 19 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Option Exercise26.497,000185,430302,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Sale77.107,000539,700295,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise26.497,000185,430302,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale77.687,000543,760295,652Mar 15 08:26 PM
GREY MICHAEL GDirectorMar 05Option Exercise26.495,000132,45047,840Mar 09 05:59 PM
GREY MICHAEL GDirectorMar 05Sale76.285,000381,40042,840Mar 09 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Option Exercise26.497,000185,430302,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Sale83.587,000585,060295,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Option Exercise26.497,000185,430302,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Sale85.087,000595,560295,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Option Exercise26.498,000211,920303,552Feb 18 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Sale84.548,000676,320295,552Feb 18 09:45 PM
LAWLIS V BRYANDirectorFeb 16Option Exercise26.497,500198,67526,350Feb 18 06:43 PM
LAWLIS V BRYANDirectorFeb 16Sale87.417,500655,57518,850Feb 18 06:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Option Exercise26.498,334220,768303,886Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Sale82.678,334688,972295,552Feb 01 07:00 PM